Venus Remedies Limited VENUSREM NSEPHARMA
Healthcare · Drug Manufacturers - Specialty & Generic · India
Venus Remedies Limited engages in the pharmaceutical business in India and internationally. It is involved in the research and development of solutions focusing on antimicrobial resistance and oncology. The company also offers analgesic, analgesic and antipyretic, antibiotic, anticoagulant, antiemetic, antiviral, cardiovascular, disinfectant and antiseptic, gastro therapy, hepatoprotective, hormones (steroid), immunostimulating agent, iron supplements, muscle relaxant, neurology, oncology, and solvent products, as well as herbal medicine. The company was incorporated in 1989 and is headquartered in Panchkula, India.
READ MORE ›₹1,280.05
+215.79% 1Y
Market & Price
Market Cap
₹1,713.05 Cr
Current Price
₹1,280.05
High / Low (52W)
₹1,280.05 / ₹405.35
Beta
0.15
Valuation
Stock P/E
16.64
Industry PE
37.60
Forward P/E
-
PEG Ratio
-
Book Value
₹444.62
Price to Book
2.88
P/S
2.23
EV/EBITDA
11.00
Dividend Yield
0.78%
Profitability & Returns
ROCE
19.39%
ROE
16.79%
ROA
9.69%
Profit Margin
13.35%
Op Margin
21.84%
EPS (Latest Qtr)
₹35.53
EPS (TTM)
₹76.93
Balance Sheet & Liquidity
Debt/Equity
1.87
Quick Ratio
1.33
Current Ratio
2.44
Debt
₹12.41 Cr
Total Assets
₹853.70 Cr
Current Assets
₹395.20 Cr
Working Capital
₹233.44 Cr
Ownership
Promoter Holding
48.62%
Chg in Prom Hold
-
FII / Inst Holding
1.15%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
₹1,619.94 Cr
Total Revenue (TTM)
₹769.60 Cr
EBITDA
₹147.28 Cr
Free Cash Flow
₹93.44 Cr
Operating Cash Flow
₹155.77 Cr
Shares Outstanding
₹1.34 Cr
Gross Margin
49.68%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
11.62%
Profit 5Y
56.99%
Revenue (YoY)
33.00%
Earnings (YoY)
126.40%
PROS
- Compounding revenue at 11.6% over 5 years.
- Profit CAGR of 57.0% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- RSI at 77 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VENUSREM Venus Remedies Limited NSEPHARMA | 1,280.05 | 16.64 | ₹1,713.05 Cr | 0.78% | 19.39% | 16.79% | 11.62% | 56.99% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,799.20 | 37.59 | ₹4.32 L Cr | 0.92% | 17.94% | 14.72% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 6,667.00 | 68.97 | ₹1.77 L Cr | 0.45% | 18.96% | 16.19% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,410.80 | 68.96 | ₹1.49 L Cr | 0.86% | 9.06% | 16.98% | 13.27% | 20.21% |
| 5 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,401.00 | 29.16 | ₹1.13 L Cr | 0.93% | 14.88% | 11.74% | 7.23% | 11.45% |
| 6 | DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA | 1,303.50 | 25.90 | ₹1.09 L Cr | 0.61% | 14.00% | 11.83% | 10.96% | -2.35% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,077.70 | 21.51 | ₹1.08 L Cr | 0.09% | 19.24% | 18.32% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,267.70 | 19.49 | ₹1.04 L Cr | 0.53% | 28.42% | 26.91% | 19.10% | 131.46% |
| 9 | MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA | 2,375.60 | 51.29 | ₹98,090.71 Cr | 0.08% | 13.78% | 12.45% | 17.73% | 14.28% |
Ad space
Quarterly Results
Figures in INR.
| Metric | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | - | 176.52 Cr | 197.66 Cr | 131.90 Cr | 192.75 Cr | 180.26 Cr | 259.40 Cr |
| Cost of Revenue | - | 110.20 Cr | 103.06 Cr | 74.15 Cr | 107.31 Cr | 86.25 Cr | 119.56 Cr |
| Gross Profit | - | 66.32 Cr | 94.60 Cr | 57.75 Cr | 85.44 Cr | 94.01 Cr | 139.84 Cr |
| Operating Expenses | - | 53.71 Cr | 67.62 Cr | 53.83 Cr | 60.65 Cr | 63.05 Cr | 83.18 Cr |
| Operating Income | - | 12.61 Cr | 26.98 Cr | 3.92 Cr | 24.79 Cr | 30.96 Cr | 56.66 Cr |
| EBITDA | - | 30.30 Cr | 35.76 Cr | 18.79 Cr | 32.67 Cr | 40.04 Cr | 68.38 Cr |
| Interest Expense | - | 1.00 L | 1.00 L | 1.00 L | 1.00 L | 1.00 L | 1.00 L |
| Pretax Income | - | 24.88 Cr | 31.04 Cr | 12.60 Cr | 26.49 Cr | 33.47 Cr | 61.61 Cr |
| Tax Provision | - | 5.28 Cr | 10.04 Cr | 3.01 Cr | 6.36 Cr | 7.89 Cr | 14.11 Cr |
| Net Income | - | 19.60 Cr | 21.00 Cr | 9.60 Cr | 20.13 Cr | 25.58 Cr | 47.49 Cr |
| Diluted EPS | 2.63 | 14.66 | 15.71 | 7.18 | 15.06 | 19.14 | 35.53 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 553.38 Cr | 591.45 Cr | 652.89 Cr | 769.60 Cr |
| Cost of Revenue | - | 345.36 Cr | 373.19 Cr | 378.62 Cr | 387.27 Cr |
| Gross Profit | - | 208.02 Cr | 218.26 Cr | 274.27 Cr | 382.33 Cr |
| Operating Expenses | - | 180.29 Cr | 185.10 Cr | 228.24 Cr | 260.72 Cr |
| Operating Income | - | 27.73 Cr | 33.16 Cr | 46.03 Cr | 121.61 Cr |
| EBITDA | - | 70.35 Cr | 71.18 Cr | 94.40 Cr | 159.87 Cr |
| Interest Expense | - | 11.80 L | 9.37 L | 7.00 L | 4.00 L |
| Pretax Income | - | 37.93 Cr | 44.64 Cr | 71.82 Cr | 134.16 Cr |
| Tax Provision | - | 11.36 Cr | 16.15 Cr | 26.51 Cr | 30.87 Cr |
| Net Income | - | 26.57 Cr | 28.49 Cr | 45.31 Cr | 102.78 Cr |
| Diluted EPS | - | 19.88 | 21.31 | 33.89 | 76.89 |
Compounded Sales Growth
| 5 Years: | 11.62% |
| 1 Year: | 33.00% |
Compounded Profit Growth
| 5 Years: | 56.99% |
| 1 Year: | 126.40% |
Stock Price Performance
| 1 Year: | +215.79% |
| 6 Months: | +82.62% |
| 3 Months: | +71.29% |
| 1 Month: | +37.15% |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 601.08 Cr | 626.82 Cr | 715.72 Cr | 853.70 Cr |
| Current Assets | - | 322.83 Cr | 359.52 Cr | 451.72 Cr | 395.20 Cr |
| Cash & Equivalents | - | 21.21 Cr | 48.96 Cr | 57.52 Cr | 25.12 Cr |
| Inventory | - | 119.94 Cr | 121.69 Cr | 100.49 Cr | 129.37 Cr |
| Receivables | - | 76.66 Cr | 80.50 Cr | 112.22 Cr | 103.28 Cr |
| Total Liabilities | - | 140.74 Cr | 139.27 Cr | 154.77 Cr | 189.95 Cr |
| Current Liabilities | - | 82.57 Cr | 79.42 Cr | 136.29 Cr | 161.76 Cr |
| Long Term Debt | 38.68 Cr | 38.68 Cr | 38.68 Cr | 0 | - |
| Total Debt | - | 42.29 Cr | 41.33 Cr | 1.69 Cr | 12.41 Cr |
| Total Equity | - | 460.34 Cr | 487.55 Cr | 560.95 Cr | 663.75 Cr |
| Shares Outstanding | - | 1.34 Cr | 1.34 Cr | 1.34 Cr | 1.34 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 36.63 Cr | 37.29 Cr | 86.45 Cr | 155.77 Cr |
| Investing Cash Flow | - | -50.83 Cr | -7.21 Cr | -76.25 Cr | -181.57 Cr |
| Financing Cash Flow | - | -56.75 L | -1.08 Cr | -1.03 Cr | -3.12 Cr |
| Capital Expenditure | - | -7.82 Cr | -13.52 Cr | -18.08 Cr | -37.70 Cr |
| Free Cash Flow | - | 28.81 Cr | 23.77 Cr | 68.37 Cr | 118.07 Cr |
| Net Change in Cash | - | -14.77 Cr | 28.99 Cr | 9.17 Cr | -28.92 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 37.6% | 36.9% | 42.0% | 49.7% |
| Operating Margin % | - | 5.0% | 5.6% | 7.1% | 15.8% |
| Net Margin % | - | 4.8% | 4.8% | 6.9% | 13.4% |
| ROE % | - | 5.8% | 5.8% | 8.1% | 15.5% |
| ROCE % | - | 5.3% | 6.1% | 7.9% | 17.6% |
Shareholding Pattern
Insiders
48.62%
Institutions
1.15%
Public Float
2.23%
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VENUSREM
No recent headlines available.